Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 18, 2019
FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management
Andréas Perrier-Cornet, Aurélien Philippe, Thierry Lambert, et al.
Therapeutic Advances in Hematology
|
September 14, 2018
Practical aspects of extended half-life products for the treatment of haemophilia
Thierry Lambert, Gary Benson, Gerry Dolan, et al.
Thrombosis and Haemostasis
|
January 9, 2015
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project
Kathelijn Fischer, Riita Lassila, Flora Peyvandi, et al.
Blood Reviews
|
August 23, 2017
Haemophilia B: Where are we now and what does the future hold?
Gerry Dolan, Gary Benson, Anne Duffy, et al.
Molecular Microbiology
|
June 21, 2013
The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance
Fariza Ammam, Djalal Meziane-Cherif, Dominique Mengin-Lecreulx, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 2, 2025
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, et al.
Research and Practice in Thrombosis and Haemostasis
|
July 19, 2024
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, et al.
Thrombosis and Haemostasis
|
January 25, 2008
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting
Roberto Musso, Elena Santagostino, Albert Faradji, et al.
Blood
|
September 17, 2005
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, et al.
European Journal of Haematology
|
August 20, 2014
Switching treatments in haemophilia: is there a risk of inhibitor development?
Elena Santagostino, Günter Auerswald, Gary Benson, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 18, 2019
FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management
Andréas Perrier-Cornet, Aurélien Philippe, Thierry Lambert, et al.
Therapeutic Advances in Hematology
|
September 14, 2018
Practical aspects of extended half-life products for the treatment of haemophilia
Thierry Lambert, Gary Benson, Gerry Dolan, et al.
Thrombosis and Haemostasis
|
January 9, 2015
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project
Kathelijn Fischer, Riita Lassila, Flora Peyvandi, et al.
Blood Reviews
|
August 23, 2017
Haemophilia B: Where are we now and what does the future hold?
Gerry Dolan, Gary Benson, Anne Duffy, et al.
Molecular Microbiology
|
June 21, 2013
The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance
Fariza Ammam, Djalal Meziane-Cherif, Dominique Mengin-Lecreulx, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
April 2, 2025
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, et al.
Research and Practice in Thrombosis and Haemostasis
|
July 19, 2024
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, et al.
Thrombosis and Haemostasis
|
January 25, 2008
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting
Roberto Musso, Elena Santagostino, Albert Faradji, et al.
Blood
|
September 17, 2005
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A
Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, et al.
European Journal of Haematology
|
August 20, 2014
Switching treatments in haemophilia: is there a risk of inhibitor development?
Elena Santagostino, Günter Auerswald, Gary Benson, et al.
Page
of 8